Zobrazeno 11 - 20
of 726
pro vyhledávání: '"Egbert F. Smit"'
Autor:
Rolof G.P. Gijtenbeek, Vincent van der Noort, Joachim G.J.V. Aerts, Jeske A. Staal-van den Brekel, Egbert F. Smit, Frans H. Krouwels, Frank A. Wilschut, T. Jeroen N. Hiltermann, Wim Timens, Ed Schuuring, Joost D.J. Janssen, Martijn Goosens, Paul M. van den Berg, A. Joop de Langen, Jos A. Stigt, Ben E.E.M. van den Borne, Harry J.M. Groen, Wouter H. van Geffen, Anthonie J. van der Wekken
Publikováno v:
ERJ Open Research, Vol 8, Iss 4 (2022)
Introduction Previous studies have shown interference between epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and chemotherapy in the cell cycle, thus reducing efficacy. In this randomised controlled trial we investigated whether i
Externí odkaz:
https://doaj.org/article/7a4d1f9500d043fca5a9dd6a08afeeba
Autor:
Scott N. Gettinger, MD, Rudolf M. Huber, MD, PhD, Dong-Wan Kim, MD, PhD, Lyudmila Bazhenova, MD, Karin Holmskov Hansen, MD, Marcello Tiseo, MD, Corey J. Langer, MD, FACP, Luis G. Paz-Ares Rodríguez, MD, PhD, Howard L. West, MD, Karen L. Reckamp, MD, MS, Glen J. Weiss, MD, Egbert F. Smit, MD, PhD, Maximilian J. Hochmair, MD, Sang-We Kim, MD, PhD, Myung-Ju Ahn, MD, PhD, Edward S. Kim, MD, FACP, Harry J.M. Groen, MD, PhD, Joanna Pye, MS, Yuyin Liu, PhD, Pingkuan Zhang, MD, Florin Vranceanu, MD, PhD, D. Ross Camidge, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 9, Pp 100385- (2022)
Introduction: We report brigatinib long-term efficacy and safety from phase 1/2 and phase 2 (ALTA) trials in ALK–rearrangement positive (ALK+) NSCLC. Methods: The phase 1/2 study evaluated brigatinib 30 to 300 mg/d in patients with advanced maligna
Externí odkaz:
https://doaj.org/article/78d40f5a880944a8b24323de142222e5
Autor:
Mandy Gruijs, Carolien Zeelen, Tessa Hellingman, Jasper Smit, Frank J. Borm, Geert Kazemier, Chris Dickhoff, Idris Bahce, Joop de Langen, Egbert F. Smit, Koen J. Hartemink, Marjolein van Egmond
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 1, p 21 (2022)
Circulating tumor cells (CTCs) have been detected in many patients with different solid malignancies. It has been reported that presence of CTCs correlates with worse survival in patients with multiple types of cancer. Several techniques have been de
Externí odkaz:
https://doaj.org/article/764664954ded4fb1819a90ad64913b7c
Autor:
Liesbeth M. Hondelink, MD, Merel Jebbink, MD, Jan H. von der Thüsen, MD, PhD, Danielle Cohen, MD, PhD, Hendrikus J. Dubbink, PhD, Marthe S. Paats, MD, PhD, Anne-Marie C. Dingemans, MD, PhD, Adrianus J. de Langen, MD, PhD, Mirjam C. Boelens, PhD, Egbert F. Smit, MD, PhD, Pieter E. Postmus, MD, PhD, Tom van Wezel, PhD, Kim Monkhorst, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 12, Pp 100252- (2021)
Introduction: With the approval of first-line osimertinib treatment in stage IV EGFR-mutated NSCLC, detection of resistance mechanisms will become increasingly important—and complex. Clear guidelines for analyses of these resistance mechanisms are
Externí odkaz:
https://doaj.org/article/15653a46b49e44dca1398d582c62eabe
Autor:
Stefano Trebeschi, Zuhir Bodalal, Thierry N. Boellaard, Teresa M. Tareco Bucho, Silvia G. Drago, Ieva Kurilova, Adriana M. Calin-Vainak, Andrea Delli Pizzi, Mirte Muller, Karlijn Hummelink, Koen J. Hartemink, Thi Dan Linh Nguyen-Kim, Egbert F. Smit, Hugo J. W. L. Aerts, Regina G. H. Beets-Tan
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
BackgroundCheckpoint inhibitors provided sustained clinical benefit to metastatic lung cancer patients. Nonetheless, prognostic markers in metastatic settings are still under research. Imaging offers distinctive advantages, providing whole-body infor
Externí odkaz:
https://doaj.org/article/ffb91a99007c454486ad28fdf5ff1d56
Autor:
Guilherme D. Kolinger, David Vállez García, Gerbrand M. Kramer, Virginie Frings, Egbert F. Smit, Adrianus J. de Langen, Rudi A. J. O. Dierckx, Otto S. Hoekstra, Ronald Boellaard
Publikováno v:
EJNMMI Research, Vol 9, Iss 1, Pp 1-12 (2019)
Abstract Background Total metabolic active tumour volume (TMATV) and total tumour burden (TTB) are increasingly studied as prognostic and predictive factors in non-small cell lung cancer (NSCLC) patients. In this study, we investigated the repeatabil
Externí odkaz:
https://doaj.org/article/3d713e086e37471f9cb28544adbb8e47
Autor:
Jana Fassunke, Fabienne Müller, Marina Keul, Sebastian Michels, Marcel A. Dammert, Anna Schmitt, Dennis Plenker, Jonas Lategahn, Carina Heydt, Johannes Brägelmann, Hannah L. Tumbrink, Yannic Alber, Sebastian Klein, Alena Heimsoeth, Ilona Dahmen, Rieke N. Fischer, Matthias Scheffler, Michaela A. Ihle, Vanessa Priesner, Andreas H. Scheel, Svenja Wagener, Anna Kron, Konrad Frank, Katia Garbert, Thorsten Persigehl, Michael Püsken, Stefan Haneder, Bernhard Schaaf, Ernst Rodermann, Walburga Engel-Riedel, Enriqueta Felip, Egbert F. Smit, Sabine Merkelbach-Bruse, H. Christian Reinhardt, Stefan M. Kast, Jürgen Wolf, Daniel Rauh, Reinhard Büttner, Martin L. Sos
Publikováno v:
Nature Communications, Vol 9, Iss 1, Pp 1-13 (2018)
Acquired resistance to targeted drugs remains a major clinical challenge in lung adenocarcinoma patients. Here, the authors show how the acquired EGFR G724S mutation induces resistance to third-generation EGFR inhibitors and why the mutant kinase rem
Externí odkaz:
https://doaj.org/article/d0509a8e9f1241e6a692b9bd9e5d0a9b
Autor:
James Chih-Hsin Yang, MD, PhD, Karen L. Reckamp, MD, Young-Chul Kim, MD, PhD, Silvia Novello, MD, PhD, Egbert F. Smit, MD, PhD, Jong-Seok Lee, MD, PhD, Wu-Chou Su, MD, Wallace L. Akerley, MD, Collin M. Blakely, MD, PhD, Harry J.M. Groen, MD, PhD, Lyudmila Bazhenova, MD, Enric Carcereny Costa, MD, Rita Chiari, MD, PhD, Te-Chun Hsia, MD, PhD, Tony Golsorkhi, MD, Darrin Despain, MStat, Danny Shih, BA, Sanjay Popat, BSc, MBBS, FRCP, PhD, Heather Wakelee, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 2, Pp 100114- (2021)
Introduction: The TIGER-3 (NCT02322281) study was initiated to compare the efficacy and safety of rociletinib, a third-generation EGFR tyrosine kinase inhibitor (TKI) that targets EGFR T790M and common EGFR-activating mutations, versus chemotherapy i
Externí odkaz:
https://doaj.org/article/3960fcdf0ad54bcf8d21572f501bc5e5
Autor:
Krijn K. Dijkstra, Kim Monkhorst, Luuk J. Schipper, Koen J. Hartemink, Egbert F. Smit, Sovann Kaing, Rosa de Groot, Monika C. Wolkers, Hans Clevers, Edwin Cuppen, Emile E. Voest
Publikováno v:
Cell Reports, Vol 31, Iss 5, Pp - (2020)
Summary: Clinical implementation of tumor organoids for personalized medicine requires that pure tumor organoids can be reliably established. Here, we present our experience with organoid cultures from >70 non-small cell lung cancer (NSCLC) samples.
Externí odkaz:
https://doaj.org/article/b469827b6c1c427c86f583c772baa165
Autor:
Deirdre M.H.J. ten Berge, Daniel P. Hurkmans, Ilse den Besten, Jeroen S. Kloover, Ron H.J. Mathijssen, Reno Debets, Egbert F. Smit, Joachim G.J.V. Aerts
Publikováno v:
ERJ Open Research, Vol 5, Iss 4 (2019)
Background Immune checkpoint inhibitors have emerged as a standard of care treatment for non-small cell lung cancer (NSCLC). To get insight into variations in tumour growth kinetics and their potential predictive values for outcome, we evaluated tumo
Externí odkaz:
https://doaj.org/article/3899781f3cc34e568c8c220b1edb35f8